
NEUROLOGY AND NEUROBIOLOGY

VOLUME 8A



CATECHOLAMINES

Part A: Basic and Peripheral Mechanisms

Editors
Earl Usdin
Arvid Carlsson
Annica Dahlström
Jörgen Engel

Alan R. Liss, Inc., New York

CATECHOLAMINES

Part A: Basic and Peripheral Mechanisms

**Proceedings of the Fifth International Catecholamine
Symposium, held in Göteborg, Sweden, June 12–16, 1983**

Editors

Earl Usdin

Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine
Irvine, California

Arvid Carlsson

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

Annica Dahlström

Institute of Neurobiology
University of Göteborg
Göteborg, Sweden

Jörgen Engel

Department of Pharmacology
University of Göteborg
Göteborg, Sweden

ALAN R. LISS, INC., NEW YORK

Address all inquiries to the Publisher
Alan R. Liss, Inc., 150 Fifth Avenue, New York, NY 10011

Copyright © 1984 Alan R. Liss, Inc.

Printed in the United States of America.

Under the conditions stated below the owner of copyright for this book hereby grants permission to users to make photocopy reproductions of any part or all of its contents for personal or internal organizational use, or for personal or internal use of specific clients. This consent is given on the condition that the copier pay the stated per-copy fee through the Copyright Clearance Center, Incorporated, 21 Congress Street, Salem, MA 01970, as listed in the most current issue of "Permissions to Photocopy" (Publisher's Fee List, distributed by CCC, Inc.), for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Library of Congress Cataloging in Publication Data

International Catecholamine Symposium (5th : 1983 :
Göteborg, Sweden)

Catecholamines : proceedings of the Fifth International
Catecholamine Symposium, Held in Göteborg, Sweden,
June 12-16, 1983.

Includes bibliographies and indexes.

Contents: pt. A. Basic and peripheral mechanisms--
pt. B. Neuropharmacology and central nervous system--
theoretical aspects--pt. C. Neuropharmacology and central
nervous system--therapeutic aspects.

1. Catecholamines--Congresses. 2. Adrenergic
mechanisms--Congresses. 3. Catecholamines--Therapeutic
use--Congresses. 4. Neuropharmacology--Congresses.
I. Usdin, Earl. II. Title. [DNLM: 1. Catecholamines--
Congresses. WI NE337B v.8 / WK 725 I59 1983c]
QP801.C3315 1983 615'.78 84-3967
ISBN 0-8451-2798-5 (set)

CATECHOLAMINES

Part A: Basic and Peripheral Mechanisms

Neurology and Neurobiology

EDITORS: Victoria Chan-Palay and Sanford L. Palay

The Harvard Medical School

ADVISORY BOARD

Günter Baumgartner

University Hospital, Zurich

Masao Ito

Tokyo University

Bruce McEwen

Rockefeller University

William D. Willis, Jr.

The University of Texas, Galveston

Gösta Jonsson

Karolinska University

Volume 1

Cytochemical Methods in Neuroanatomy

Victoria Chan-Palay and Sanford L. Palay, *Editors*

Volume 2

Basic Mechanisms of Neuronal Hyperexcitability

Herbert H. Jasper and Nico M. van Gelder, *Editors*

Volume 3

Anorexia Nervosa: Recent Developments in Research

Padraig L. Darby, Paul E. Garfinkel, David M. Garner, and Donald V. Coscina, *Editors*

Volume 4

Clinical and Biological Aspects of Peripheral Nerve Diseases

Leontino Battistin, George A. Hashim, and Abel Lajtha, *Editors*

Volume 5

The Physiology of Excitable Cells

Alan D. Grinnell and William J. Moody, Jr., *Editors*

Volume 6

Developing and Regenerating Vertebrate Nervous Systems

Penelope W. Coates, Roger R. Markwald, and Alexander D. Kenny, *Editors*

Volume 7

Glutamine, Glutamate, and GABA in the Central Nervous System

Leif Hertz, Elling Kvamme, Edith G. McGeer, and Arne Schousboe, *Editors*

Volume 8

Catecholamines

Earl Usdin, Arvid Carlsson, Annica Dahlström, and Jörgen Engel, *Editors*

Published in three volumes:

Part A: Basic and Peripheral Mechanisms

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

Contributors

W. Mark Abbott, Department of Biochemistry, The Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK [251]

J.E. Adler, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

T.E. Adrian, Royal Postgraduate Medical School, Hammersmith Hospital, University of London, London W12 0HS, UK [133]

O. Almgren, Department of Cardiovascular Pharmacology, AB Hässle, S-43183 Mölndal, Sweden [357]

C. Andre, Department of Protein Chemistry, Institute of Molecular Biology, Free University of Brussels, VUB, B-1640 St. Genesius Rode, Belgium [271]

Laurice Badino, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 [319]

E. Edward Baetge, Neurobiology Laboratory, Cornell University Medical College, New York, NY 10021 [203]

L. Baizer, Department of Pharmacology, University of Colorado School of Medicine, Denver, CO 80262 [173]

Jeffrey L. Benovic, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

P.M.M. Bircham, Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, UK [133]

Ira B. Black, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

Asa G.H. Blakeley, Department of Physiology, University of Leicester, Leicester LE1 7RH, UK [65]

Hermann Blaschko, Department of Pharmacology, Oxford University, Oxford OX2 6SH, UK [3]

S.R. Bloom, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS, UK [133]

M.C. Bohn, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

C. Boni, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

S. Bottari, Department of Gynecology and Obstetrics, Institute of Molecular Biology, Free University of Brussels, VUB, B-1640 St. Genesius Rode, Belgium [271]

M. Buda, Institut National de la Santé et de la Recherche Médicale, Hôpital Ste-Eugénie, 69230 Saint-Genis-Laval, France [211]

Nguyen T. Buu, Clinical Research Institute of Montreal, Montreal, Quebec H2W 1R7, Canada [337]

Marc G. Caron, Department of Medicine, Duke University Medical Center, Durham, NC 27710 [283]

John P. Chalmers, Department of Medicine, Flinders Medical Centre, Adelaide, 5042 Australia [365]

Y. Citri, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel [279]

H.L. Cohen, Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [369]

E. Costa, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, St. Elizabeth's Hospital, Washington, DC 20032 [153]

The numbers in brackets are opening page numbers of each author's article.

A complete list of conference participants appears in Catecholamines, Part C.

x / Contributors

John F. DeBernardis, Division of Cardiovascular Research, Abbott Laboratories, Abbott Park, North Chicago, IL 60064 [283]

Robert M. DeMarinis, Department of Medicinal Chemistry, Smith Kline and French Laboratories, Philadelphia, PA 19101 [283]

Gaetano Di Chiara, Y Porcell 4, Institute of Pharmacology, Cagliari, Italy [167]

Kenneth E.J. Dickenson, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

S.M. DiRusso, Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [369]

L.P. Eberle, Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [369]

Barbara Eddy, Department of Molecular Immunology, Roswell Park Memorial Institute, Buffalo, NY 14263 [293]

A.V. Edwards, The Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, UK [133]

N. Faucon Biguet, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

Claire M. Fraser, Department of Molecular Immunology, Roswell Park Memorial Institute, Buffalo, NY 14263 [293]

Bertil B. Fredholm, Department of Pharmacology, Karolinska Institute, S-104 01 Stockholm, Sweden [169]

Gabriel Fried, Department of Physiology, Karolinska Institute, S-104 01 Stockholm, Sweden [45]

Hitoshi Fujisawa, Department of Biochemistry, Asahikawa Medical College, Asahikawa 078-11, Japan [183]

Robert J. George, Department of Neurobiology and Anatomy, University of Texas Medical School, Houston, TX 77025 [195]

M.A. Ghatel, Royal Postgraduate Medical School, Hammersmith Hospital, University of London, London W12 0HS, UK [133]

J.S. Gillespie, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, UK [41]

Menek Goldstein, Department of Psychiatry, Neurochemistry Research Unit, New York University Medical Center, New York, NY 10016 [189, 237]

P.M. Gootman, Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [369]

Lloyd Greene, Department of Pharmacology, New York University Medical Center, New York, NY 10016 [189]

Paul Greengard, Laboratory of Molecular & Cellular Neuroscience, Rockefeller University, New York, NY 10021 [9]

B. Grima, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

Horst Grobecker, Department of Pharmacology, University of Regensburg, D-8400 Regensburg, FRG [367]

A. Guidotti, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

Jan Häggendal, Department of Pharmacology, University of Göteborg, S-400 33 Göteborg, Sweden [105]

I. Hanbauer, Hypertension-Endocrine Branch, National Heart and Lung Institute, NIH, Bethesda, MD 20205 [153]

John W. Haycock, Department of Neurobiology and Anatomy, University of Texas Medical School, Houston, TX 77025 [195]

Sarah L. Heald, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

Paul Hjendahl, Department of Pharmacology, Karolinska Institute, S-104 01 Stockholm, Sweden [163]

D. Hoyer, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 [259]

Leighton Y. Huey, Departments of Psychiatry, Veterans Administration Medical Center and University of California, San Diego, La Jolla, CA 92093 [327]

David S. Janowsky, Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093 [303, 327]

Bevyn Jarrott, Department of Clinical Pharmacology, University of Melbourne, Heidelberg 3084, Australia [361]

Tong H. Joh, Neurobiology Laboratory, Cornell University Medical College, New York, NY 10021 [203]

G.M. Jonakait, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

Colin T. Jones, Nuffield Institute for Medical Research, University of Oxford, Oxford OX3 9DS, UK [111,121,143]

G. Jonsson, Department of Histology, Karolinska Institute, S-104 01 Stockholm, Sweden [145]

Lewis L. Judd, Departments of Psychiatry, Veterans Administration Medical Center and University of California, San Diego, La Jolla, CA 92093 [327]

J.F. Julien, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

H. Kageyama, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

Y. Kataoka, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

D.M. Katz, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

C. Kellogg, Department of Psychology, University of Rochester, Rochester, NY 14627 [145]

Brian Kennedy, Department of Medicine, University of California, San Diego, La Jolla, CA 92093 [327]

J.A. Kessler, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

J. Kirilovsky, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel [279]

Richard Klein, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, Jackson, MS 39216 [45]

Irwin J. Kopin, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20205 [347]

Otto Kuchel, Clinical Research Institute of Montreal, Montreal, Quebec H2W 1R7, Canada [337]

Richard Kvetňanský, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava 83306, Czechoslovakia [367]

P.M. Laduron, Department of Biochemical Pharmacology, Janssen Pharmaceutica, B-2340 Beerse, Belgium [243]

Hugo Lagercrantz, Department of Pediatrics and Nobel Institute of Neurophysiology, Karolinska Institute, S-104 01 Stockholm, Sweden [45,111,113,143]

A. Lamouroux, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

Story C. Landis, Department of Neurobiology, Harvard Medical School, Boston, MA 02115 [23]

T.A. Langan, Department of Pharmacology, University of Colorado School of Medicine, Denver, CO 80262 [173]

Kwan Y. Lee, Department of Psychiatry, Neurochemistry Research Unit, New York University Medical Center, New York, NY 10016 [189]

L.M. Fredrik Leeb-Lundberg, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

Robert J. Lefkowitz, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

Jow Y. Lew, Department of Psychiatry, Neurochemistry Research Unit, New York University Medical Center, New York, NY 10016 [237]

J.E. Leysen, Department of Biochemical Pharmacology, Janssen Pharmaceutica, B-2340 Beerse, Belgium [225]

Leslie Lilly, Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8, Canada [293]

Walter Lovenberg, Biochemical Pharmacology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20205 [307]

J. Mallet, Institut de Microbiologie, Université Paris-Sud, 91405 Orsay, France [211]

K.A. Markey, Department of Neurology, Cornell University Medical College, New York, NY 10021 [31]

xii / Contributors

A. Mathie, Department of Physiology, University of Leicester, Leicester LE1 7RH, UK [65]

G.P. McGregor, Royal Postgraduate Medical School, Hammersmith Hospital, University of London, London W12 OHS, UK [133]

Michael J. Meldrum, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 [319]

P.B. Molinoff, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 [259]

Erich O. Muscholl, Pharmacology Department, University of Mainz, D-6500 Mainz, FRG [109]

Ikuko Nagatsu, Department of Anatomy, School of Medicine, Fujito-Gakuen University, Toyoake, Aichi 470-11, Japan [219]

Toshiharu Nagatsu, Laboratory of Cell Physiology, Department of Life Chemistry, Graduate School at Nagatsuta, Tokyo Institute of Technology, Yokohama 227, Japan [219]

Eric J. Nestler, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510 [9]

B.N. O'Connor, Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, UK [133]

Sachiko Okuno, Department of Biochemistry, Asahikawa Medical College, Asahikawa 078-11, Japan [183]

Lars Oreland, Department of Pharmacology, University of Umeå, S-901 87 Umeå, Sweden [169]

P. Panula, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

David M. Paton, Department of Pharmacology, University of Auckland, Auckland, New Zealand [165]

S.A. Petersen, Department of Physiology, University of Leicester, Leicester LE1 7RH, UK [65]

T.T. Quach, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

John W. Regan, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

Donald J. Reis, Neurology Laboratory, Cornell University Medical College, New York, NY 10021 [203, 365]

E.E. Reynolds, Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 [259]

Samuel Craig Risch, Departments of Psychiatry, Veterans Administration Hospital and University of California, San Diego, La Jolla, CA 92093 [327]

Margaret M. Roebuck, Nuffield Institute for Medical Research, University of Oxford, Oxford OX3 9DS, UK [121]

M. Elizabeth Ross, Neurobiology Laboratory, Cornell University Medical College, New York, NY 10021 [203]

A.P. Rudell, Department of Physiology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [369]

Charles O. Rutledge, Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS 66045 [149]

Esther L. Sabban, Department of Psychiatry, Neurochemistry Research Unit, New York University Medical Center, New York, NY 10016 [189]

Jayne Schaber, Department of Molecular Immunology, Roswell Park Memorial Institute, Buffalo, NY 14263 [293]

M. Schramm, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel [279]

J.P. Schwartz, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032 [153]

John Seeley, Department of Pharmacology, New York University Medical Center, New York, NY 10016 [189]

Philip Seeman, Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8, Canada [293]

Frederic J. Seidler, Department of Pharmacology, Duke University Medical Center, Durham, NC 27710 [129]

Y. Severne, Department of Protein Chemistry, Institute of Molecular Biology, Free University of Brussels, VUB, B-1640 St. Genesius Rode, Belgium [271]

Theodore A. Slotkin, Department of Pharmacology, Duke University Medical Center, Durham, NC 27710 [129]

Michael J. Sole, Department of Medicine, University of Toronto, Toronto, Ontario M5G 1L7 Canada [309]

Robert Stitzel, Department of Pharmacology and Toxicology, West Virginia University, Morgantown, WV 26506 [361]

Philip G. Strange, Department of Biochemistry, The Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK [251]

A.W. Tank, Department of Pharmacology, University of Colorado School of Medicine, Denver, CO 80262 [173]

Åsa Thureson-Klein, Department of Pharmacology and Toxicology, The University of Mississippi Medical Center, Jackson, MS 39216 [45,79]

Ullrich Trendelenburg, Department of Pharmacology, University of Würzburg, D-8700 Würzburg, FRG [357]

Börje Uvnäs, Department of Pharmacology, Karolinska Institute, S-104 01 Stockholm, Sweden [55,163]

G. Vauquelin, Department of Protein Chemistry, Institute of Molecular Biology, Free University of Brussels, VUB, B-1640 St. Genesius Rode, Belgium [271]

J. Craig Venter, Department of Molecular Immunology, Roswell Park Memorial Institute, Buffalo, NY 14263 [293]

Marthe Vogt, Institute of Animal Physiology, Agricultural Research Council, Babraham, Cambridge CB2 4AT, UK [5]

Arun R. Wakade, Department of Pharmacology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [89]

Taruna D. Wakade, Department of Pharmacology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203 [89]

Peter Waldmeier, CIBA-GEIGY AG, Basel, Switzerland [167]

David W. Walker, Nuffield Institute for Medical Research, University of Oxford, Oxford OX3 9DS, UK [121]

Jack C. Waymire, Department of Neurobiology and Anatomy, University of Texas Medical School, Houston, TX 77025 [195]

Norman Weiner, Department of Pharmacology, University of Colorado School of Medicine, Denver, CO 80262 [173]

Thomas C. Westfall, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 [319]

Mark Wheatley, Department of Biochemistry, The Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK [251]

Jarl E.S. Wikberg, Department of Physiology, Duke University Medical Center, Durham, NC 27710 [283]

W. Wouters, Department of Biochemical Pharmacology, Janssen Pharmaceutica, B-2340 Beerse, Belgium [243]

Chun-Sheng Xue, Department of Pharmacology, St. Louis University School of Medicine, St. Louis, MO 63104 [319]

Takashi Yamauchi, Department of Biochemistry, Asahikawa Medical College, Asahikawa 078-11, Japan [183]

N. Yanagihara, Department of Pharmacology, University of Colorado School of Medicine, Denver, CO 80262 [173]

Albert Zeller, Shriners Hospital for Crippled Children, Chicago, IL 60635 [169]

Michael Ziegler, Department of Medicine, University of California, San Diego, La Jolla, CA 92093 [327]

Contents of Parts B and C

Part B: Neuropharmacology and Central Nervous System—Theoretical Aspects

A. PRE- AND POSTSYNAPTIC REGULATORY MECHANISMS

- 1 Pre- and Postsynaptic Regulatory Mechanisms in Dopaminergic Neurons: Introduction / *Robert H. Roth*
- 2 Functional In Vitro Comparison of Striatal Pre- and Postsynaptic Dopamine Receptors / *Klaus Starke*
- 3 Evidence for Terminal Autoreceptors in Dopaminergic Neurons of the Mesocortical System / *F. Fadda, M. Marcou, Z.L. Rossetti, E. Mosca, and G.L. Gessa*
- 4 The Pharmacology of Pre- and Postsynaptic Dopamine Receptors: Differential Effects of Dopamine Receptor Agonists and Antagonists / *Nils-Erik Andén, Ture Ålander, Maria Grabowska-Andén, Bo Liljenberg, Silvana Lindgren, and Ulla Thornström*
- 5 In Vivo Biochemical and Electrophysiological Studies on the Distribution and Pharmacology of Dopamine Autoreceptors / *Michael J. Bannon, Louis A. Chiodo, Edward B. Bunney, Marina E. Wolf, Anthony A. Grace, Benjamin S. Bunney, and Robert H. Roth*
- 6 Possible Role of Protein Carboxymethylation in the Autoreceptor-Mediated Regulation of Dopamine Neurons / *Melvin L. Billingsley, Matthew P. Galloway, and Robert H. Roth*
- 7 Pre- and Postsynaptic Regulatory Mechanisms in Dopaminergic Neurons: Conclusions / *Robert H. Roth*

B. RECEPTORS

- 8 Catecholamine Receptors, Opiate Receptors, and Presynaptic Modulation of Neurotransmitter Release in the Brain / *Arie H. Mulder, Abraham L. Frankhuyzen, Johannes C. Stoof, Johan Wemer, and Anton N.M. Schoffeleer*
- 9 Biochemical and Behavioral Identification of Discriminant Benzamide Derivatives: New Tools to Differentiate Subclasses of Dopamine Receptors / *J.-C. Schwartz, M. Delandre, M.P. Martres, P. Sokoloff, P. Protais, M. Vasse, J. Costentin, P. Laibe, A. Mann, C.G. Wermuth, C. Gulat, and A. Laffite*
- 10 Light Microscopic Autoradiographic Localization of Catecholamine Receptor Binding Sites in Brain. Problems of Ligand Specificity and Use of New Ligands / *José M. Palacios*
- 11 The Physiology of Central α - and β -Adrenoceptors / *G.K. Aghajanian*
- 12 D_2 Dopamine Receptors Inhibit Adenylate Cyclase in Anterior Pituitary Lobe: A Crucial Role of Mg^{2+} in the Inhibition Mechanism / *Joël Bockaert, Alain Enjalbert, and Michèle Sebben-Perez*
- 13 Regulation of the Sensitivity of D_1 Receptors in the Prefrontal Cortex and the Nucleus Accumbens by Nondopaminergic Pathways / *J.P. Tassin, M. Reibaud, G. Blanc, J.M. Studler, and J. Glowinski*
- 14 Distribution of Effects of Catecholaminergic Agents on Local Cerebral Glucose Consumption in the Conscious Rat / *Helen E. Savaki*
- 15 Influence of Prolactin on the Regulation of the Dopamine Receptor in the Striatum / *Robert E. Hruska*
- 16 Adrenergic Agonists Alter the Intracellularly Recorded Spontaneous Activity and Postdischarge After Hyperpolarization of Pyramidal Neurons of the Rat Hippocampus In Vitro / *D.L. Gruol and G.R. Siggins*
- 17 Dopamine Receptors (Presynaptic): Summary / *D.C. German and S. Arbilla*
- 18 Dopamine Receptors (Postsynaptic): Summary / *W.J. Shoemaker and Sara Fuchs*

C. ALCOHOL EFFECTS

- 19 Regulation of Adenylate Cyclase and Chronic Ethanol Treatment in the Rat / *L. Lucchi, R.A. Rius, M.L. Barbaccia, P.F. Spano, and M. Trabucchi*
- 20 Catecholaminergic Correlates of Genetic Differences in Ethanol Sensitivity / *K. Kiianmaa and B. Tabakoff*
- 21 Central Norepinephrine Metabolism During Alcohol Intoxication in Man—Relationship to Blood Alcohol Concentration / *Stefan Borg, Hans Kvande, Dick Mossberg, and Peter Valverius*
- 22 Noradrenergic Involvement in the Cellular Actions of Ethanol / *F.E. Bloom, G.R. Siggins, S.L. Foote, D. Gruol, G. Aston-Jones, J. Rogers, Q. Pittman, and D. Staunton*
- 23 Drug Abuse and Reward: Summary / *L.A. Pohorecky and T. Lewander*

D. NEUROPEPTIDE-CATECHOLAMINE INTERACTIONS

- 24 Neuropeptide-Catecholamine Interaction: Introduction / *Tomas Hökfelt*
- 25 Catecholamines, Neuropeptide Y (NPY), and the Pancreatic Polypeptide Family: Coexistence and Interaction in the Sympathetic Response / *J.M. Lundberg, L. Terenius, T. Hökfelt, and K. Tatemoto*
- 26 Postsynaptic Effects of Neuropeptide Comodulators at Central Monoamine Synapses / *Luigi F. Agnati, Kjell Fuxe, Fabio Benfenati, Nino Battistini, Isabella Zini, Massimo Camurri, and Tomas Hökfelt*
- 27 Interaction of Neurotensin and Dopamine in Limbic Structures / *Charles B. Nemeroff, Peter W. Kalivas, and Arthur J. Prange, Jr.*
- 28 On the Inhibition by Opiates of Norepinephrine Release / *R.A. North and J.T. Williams*
- 29 Neurohypophyseal Hormones and Limbic-Midbrain Catecholamines / *Dirk H.G. Versteeg and Dicky Van Heuven-Nolsen*
- 30 Interactions Between Enkephalin and Dopamine in Rat Frontal Cortex / *Barry J. Hoffer, Michael R. Palmer, Åke Seiger, and Lars Olson*
- 31 Neurotensin- and NPY-Like Immunoreactivities in Central Catecholamine Neurons / *Tomas Hökfelt, Barry J. Everitt, Elvar Theodorsson-Norheim, Lars Terenius, Kazuhiko Tatemoto, Viktor Mutt, and Menek Goldstein*
- 32 Catecholamines and Peptides: Summary / *Marianne Schultzberg*

E. CATECHOLAMINES AND INTEGRATIVE BEHAVIORS

- 33 Catecholamine Modulation of Sensorimotor Reactivity Measured With Acoustic Startle / *Michael Davis, David Astrachan, John Kehne, Randall Commissaris, and Dorothy Gallagher*
- 34 Brain Catecholamines and Motivated Behavior: Specific or Nonspecific Contributions? / *Edward M. Stricker and Michael J. Zigmond*
- 35 Conditioning of Dopamine Metabolism Using Droperidol and Bromocriptine as Unconditioned Stimuli / *Jorge Pérez-Cruet*
- 36 Alteration of Brain Catecholamine Metabolism by Environmental and Behavioral Events: An Explanation of Drug-Behavior Interactions / *Lewis S. Seiden and Thomas G. Heffner*
- 37 Norepinephrine in Learning and Memory—The Status of the Cognitive Deficit / *S.-O. Ögren, T. Archer, and S.B. Ross*
- 38 Mesecephalic Dopaminergic Neurons: Functional Role / *H. Simon and M. Le Moal*
- 39 Behavior and Catecholamines: Summary / *Johan Offermeier and Harvey J. Altman*

F. ELECTROPHYSIOLOGY

- 40 Electrophysiology of Central Dopamine Systems: Introduction / *Benjamin S. Bunney*
- 41 Electrophysiological Identification of Midbrain Dopaminergic Neurons / *Benjamin S. Bunney*
- 42 Nigral Dopaminergic Neurons: Extracellular and Intracellular Electrophysiological Characteristics / *Anthony A. Grace and Benjamin S. Bunney*
- 43 Electrophysiology of Substantia Nigra Transplants / *Suzanne M. Wuerthele, Lars Olson, William Freed, Richard Wyatt, and Barry J. Hoffer*
- 44 Modulation of Midbrain Dopamine Cell Activity / *J.R. Walters, T.H. Lanthorn, B.L. Waszczak, M.D. Baring, M. Knight, and L. Steardo*
- 45 General Anesthetics Prevent Dopaminergic Neuron Stimulation by Neuroleptics / *G. Mereu, B. Fanni, and G.L. Gessa*

- 46 Effects of Dopamine Agonists on Midbrain Dopamine Cell Activity / *R. Y. Wang, F.J. White, and M.M. Voigt*
- 47 Effects of Dopamine Antagonists on Midbrain Dopamine Cell Activity / *Louis A. Chiodo and Benjamin S. Bunney*
- 48 Dopaminergic Unit Activity in Freely Moving Animals: A Review / *Barry L. Jacobs, George F. Steinfels, and Robert E. Strecker*
- 49 Electrophysiology of Dopaminergic Neurons in the Behaving Primate / *Wolfram Schultz*
- 50 Zetidine: A New Antagonist of Dopamine Receptors in the Rat Substantia Nigra / *G.N. Woodruff and N.C. Harris*

G. NEUROENDOCRINOLOGY

- 51 Catecholaminergic and Peptidergic Control of Rat Pars Intermedia Cell Activity / *H. Meunier, L. Proulx, G. Lefevre, J. Côté, and F. Labrie*
- 52 Beta-Adrenergic Control of Adrenocorticotrophic Hormone Release From the Anterior Pituitary / *T.D. Reisine, E. Mezey, M. Palkovits, S. Heisler, and J. Axelrod*
- 53 Thyroid Hormones and Adrenergic Neurotransmitters / *Mary B. Dratman, Floy L. Crutchfield, and Janice T. Gordon*
- 54 Quantitative Chemical Neuroanatomy Gives New Insights Into the Catecholamine Regulation of the Peptidergic Neurons Projecting to the Median Eminence / *Kjell Fuxe, Luigi F. Agnati, Laura Calza, Kurt Andersson, Luciana Giardino, Fabio Benfenati, Massimo Camurri, and Menek Goldstein*
- 55 Regulation of Tuberoinfundibular Dopaminergic Neurons: The Role of Prolactin / *Kenneth E. Moore and Keith T. Demarest*
- 56 Norepinephrine-Mediated Effects of GABA on LH Release / *W. Wuttke, J. Demling, E. Fuchs, T. Mansky, H. Keck, R. Lamberts, and M. Graf*

H. METHODOLOGY AND CENTRAL CATECHOLAMINE MECHANISMS

- 57 Experimental Methods: Summary / *G. Curzon*
- 58 Central Catecholamine Mechanisms: Summary / *S.F. Leibowitz and T.W. Robbins*
- 59 Locus Coeruleus: Summary / *D. Eugene Redmond, Jr.*

Part C: Neuropharmacology and Central Nervous System—Therapeutic Aspects

A. CATECHOLAMINES IN PSYCHIATRIC DISORDERS

- 1 A Reevaluation of the Catecholamine Hypothesis in Affective Disorders / *William E. Bunney, Jr. and Blynn L. Garland*
- 2 Catecholamines and Schizophrenia: An Assessment of the Evidence / *T.J. Crow, A.J. Cross, J.A. Johnson, E.C. Johnstone, M.H. Joseph, F. Owen, D.G.C. Owens, and M. Poulter*
- 3 Psychopharmacology and Schizophrenia: Summary / *M. Ackenheil and S. Algeri*
- 4 Psychopharmacology and Schizophrenia: Summary / *B. Angrist and C. Tamminga*
- 5 Catecholamines in Affective Disorders: Summary / *Keith Wood and Ole J. Rafaelsen*

B. MOTOR MALFUNCTIONS

- 6 Catecholamine Mechanisms and Motor Malfunction: Introduction / *Thomas N. Chase*
- 7 Neuropeptides in Parkinson's Disease / *F. Javoy-Agid, H. Taquet, F. Cesselin, J. Epelbaum, D. Grouselle, A. Mauborgne, J.M. Studler, and Y. Agid*
- 8 Neurochemistry of Monoaminergic Neurons in Parkinson's Disease / *B. Scatton, F. Javoy-Agid, J.C. Montfort, and Y. Agid*
- 9 Progabide in Decompensated Parkinson's Disease: Implications of Dopaminergic-GABAergic Interactions for Levodopa-Induced Fluctuations / *Kenneth J. Bergmann, Joao C.P. Limongi, Young-Hee Lowe, Marina R. Mendoza, and Melvin D. Yahr*

xviii / Contents of Part C

- 10 Abnormal Involuntary Movements in Schizophrenia: Neurochemical Correlates and Relation to the Disease Process / *T.J. Crow, S.R. Bloom, A.J. Cross, I.N. Ferrier, E.C. Johnstone, F. Owen, D.G.C. Owens, and G.W. Roberts*
- 11 Tardive Dyskinesia: GABA Agonist Treatment / *C.A. Tamminga, G.K. Thaker, and S.T. Goldberg*
- 12 Primary (Initial) and Secondary (Tardive) Dyskinesia: Effect of Fluperlapine, a New Atypical Neuroleptic Drug / *J. Gerlach, S. Korsgaard, and U. Noring*
- 13 Studies in Experimental Tardive Dyskinesia / *Lars M. Gunne and Jan-Erik Häggström*
- 14 Monkey Models of Tardive Dyskinesia / *Edward F. Domino and Beverly Kovacic*
- 15 Comparison of the Effects on Striatal Dopamine Receptor Function of Chronic Administration of Haloperidol, Clozapine, or Sulpiride to Rats for Up to 12 Months / *N.M.J. Rupniak, S. Mann, M.D. Hall, P. Jenner, and C.D. Marsden*
- 16 Animal Models for Neuroleptic-Induced Neurological Dysfunction / *A.V. Christensen, J. Arnt, and O. Svendsen*
- 17 Catecholamine Mechanisms and Motor Malfunction: Summary / *Yves Agid and Peter Riederer*

C. CEREBROSPINAL FLUID CONCENTRATION OF AMINES AND METABOLITES

- 18 Cerebrospinal Fluid Concentrations of Amines and Metabolites: Clinical and Methodological Perspectives / *Robert M. Post*
- 19 Cerebrospinal Fluid Norepinephrine Metabolites in Depressed Patients: New Methodologies / *D.C. Jimerson, D.R. Rubinow, J.C. Ballenger, R.M. Post, and I.J. Kopin*
- 20 Psychiatric Morbidity Within the Family and Steady-State Levels of Cerebrospinal Fluid Monoamine Metabolites / *F.-A. Wiesel, L. Bjerkenstedt, J. Herlofsson, C. Härnryd, H. Nybäck, G. Oxenstierna, and G. Sedvall*
- 21 Brain and Cerebrospinal Fluid-Epinephrine in Isocarboxazide- and Zimeldine-Treated Rats / *Annette Gjerris, David I. Barry, Niels Juel Christensen, and Ole J. Rafaelsen*
- 22 Systems Theory as a Tool for Integrating Functional Interactions Among Biogenic Amines / *Kym F. Faull, Roy J. King, Philip A. Berger, and Jack D. Barchas*
- 23 Cerebrospinal Fluid Amine Metabolites and Neuroendocrine Changes in Psychoses and Suicide / *Csaba M. Banki, M. Arató, Z. Papp, and M. Kurcz*
- 24 Cerebroventricular Volume, Cerebrospinal Fluid Monoamine Metabolites, and Intellectual Performance in Schizophrenic Patients / *H. Nybäck, B.-M. Berggren, H. Nyman, G. Sedvall, and F.-A. Wiesel*
- 25 Cortical Atrophy and Enlarged Ventricles Associated With Low Levels of Cerebrospinal Fluid Monoamine Metabolites and Dopamine- β -Hydroxylase Activity in Schizophrenia / *Daniel P. Van Kammen, Lee S. Mann, David E. Sternberg, Mika Scheinin, Philip T. Ninan, Welmoet B. Van Kammen, and Markku Linnola*
- 26 Cerebrospinal Fluid Cyclic Nucleotides in Schizophrenia / *Robert H. Belmaker, Daniel Stein, Daniel Weinberger, Steve G. Potkin, and Richard J. Wyatt*

D. PHARMACOLOGY

- 27 3-(3-Hydroxyphenyl)-N-n-propylpiperidine (3-PPP)—A Novel Tool for the Characterization of Dopamine Receptors / *Arvid Carlsson*
- 28 Workshop on the Chemistry and Biology of Ring-Fluorinated Catecholamines: Summary / *Cyrus R. Creveling*

E. REGENERATION

- 29 Intrastratial Chromaffin Grafts in Experimental and Clinical Parkinsonism: First Impressions / *L. Olson, E.-O. Backlund, G. Sedvall, M. Herrera-Marschitz, U. Ungerstedt, I. Strömberg, B. Hoffer, and A. Seiger*
- 30 Implantation of Suspensions of Dissociated Dopamine Neurons in the Rat Brain / *Anders Björklund, Stephen B. Dunnett, Fred H. Gage, and Ulf Stenevi*
- 31 Transplantation of Peptidergic and Aminergic Neurons / *John R. Sladek, Jr., Don M. Gash, and Timothy J. Collier*
- 32 A Role for Exogenous Gangliosides in the Functional Recovery of Adult Lesioned Nervous System / *G. Toffano, G. Savoini, C. Aldinio, M. Valenti, G. Lombardi, F. Moroni, L.F. Agnati, and K. Fuxe*
- 33 Anatomy, Plasticity, and Regeneration: Summary / *Fred H. Gage*
- 34 Concluding Remarks: Shaking the Kaleidoscope / *M. Sandler*

Preface

HISTORICAL

Although there was some question at the Fourth International Catecholamine Symposium (4 CA) (Asilomar; September 17–22, 1978) whether or not there could/should be a Fifth Symposium, there is no question that it was most appropriate to hold the meeting in Sweden and, in particular, in Göteborg—the scientific home of Arvid Carlsson, Annica Dahlström, Jörgen Engel, and other eminent catecholaminologists. There is little question that the meeting was a success from a quantitative point of view. Qualitative success is obviously a subjective matter—to be determined by the individual attendees, and the individual readers of these proceedings' volumes. Personally, I feel the meeting was most valuable on the basis of the high degree of acceptance by invited plenary and symposia speakers and on the basis that in spite of insufficient travel support the projected attendance of 600 was passed—by about 250! Countries represented included the following: Argentina, Australia, Belgium, Canada, Chile, Czechoslovakia, Denmark, Federal Republic of Germany, Finland, France, German Democratic Republic, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, People's Republic of China, Poland, Portugal, Singapore, South Africa, Sweden, Switzerland, Taiwan, United Kingdom, United States of America, Yugoslavia.

The length of time between International Catecholamine Symposia varies. Thus, the First Symposium was held in Bethesda, Maryland, October 16–18, 1958. About seven years later, 2 CA was held July 4–9, 1969, in Milan, Italy. There was a span of eight years before the Third Symposium was held in Strasbourg, France (May 20–25, 1973). The timing between the Third and Fourth Symposia was five years as was that between the Fourth and Fifth Symposia. By a unanimous vote of a Committee of the Whole at 5 CA, it was decided that 6 CA will be held in Jerusalem, Israel (in about four years). Dr. Robert Haim Belmaker was chosen as Chairman of the Local Committee and I was chosen as Executive Secretary of 6 CA. Haim Belmaker or/and I would appreciate hearing from interested catecholaminologists.

PUBLICATION

It is impossible to satisfy the preferences of everyone. The Strasbourg proceedings were type-set; participants were allocated varying amounts of space for their manuscripts; discussions were summarized by assigned reporters. The Organizers determined who would receive how much space. Democracy was the key-word for the Asilomar proceedings: almost everyone was assigned three pages of camera-ready manuscript (the only exceptions were a few plenary keynote speakers). The number of papers required two enormous volumes (each over 1,000 pages). There were many complaints that three pages represented, essentially, a slightly extended abstract rather than a paper.

For the Göteborg meeting, we have adopted yet another format: only the plenary and symposia talks are published here—but these are published in extenso. In addition, the chairmen of voluntary paper sessions were given the option of summarizing some of the more interesting items in their sessions. We recognize that there are significant differences between the needs of a meeting and the needs of a publication. The manuscripts are not

xx / Preface

arranged as they were at the meeting, but rather in what we feel is the most logical arrangement. In turn, the papers are grouped into three volumes (available separately or as a set): A. Basic and Peripheral Mechanisms; B. Neuropharmacology and Central Nervous System—Theoretical Aspects; C. Neuropharmacology and Central Nervous System—Therapeutic Aspects. There are certain redundancies: complete Table of Contents and Index are included in each volume, as are Abbreviations. Thus, each volume is an entity; on the other hand, owners of one volume will, hopefully, see intriguing entries in the Table of Contents or Subject Index which will impel them to buy the other volumes (e.g., Merton Sandler's closing remarks are contained only in Volume III).

COMMITTEES

Honorary Presidents

M. Vogt, Cambridge (UK)

H. Blaschko, Oxford (UK)

President

A. Carlsson (Sweden)

Organizing Committee

A. Carlsson (chairman) (Sweden)	S. Kety (USA)
E. Usdin (executive secretary) (USA)	N. Kirshner (USA)
G. Aghajanian (USA)	I. Kopin (USA)
J. Axelrod (USA)	R. Kvetnansky (Czechoslovakia)
J. Barchas (USA)	S. Langer (France)
J. Belmar (Chile)	J. Leysen (Belgium)
F. Bloom (USA)	J. Maj (Poland)
A.Y. Budantsev (USSR)	P. Mandel (France)
Y.-C. Chin (Rep. of China)	T. Nagatsu (Japan)
E. Costa (USA)	O. Nedergaard (Denmark)
T. Crow (UK)	M. Palkowitz (Hungary)
L. Cubeddo (Venezuela)	A. Pletscher (Switzerland)
O. Eränkö (Finland)	D. Reis (USA)
K. Fuxe (Sweden)	J. Saavedra (USA)
S. Garattini (Italy)	M. Sandler (UK)
L. Geffen (Australia)	A. Sjoerdsma (USA)
J. Glowinski (France)	S. Snyder (USA)
M. Goldstein (USA)	T. Sourkes (Canada)
V. Gorkin (USSR)	S. Spector (USA)
P. Greengard (USA)	U. Trendelenburg (FRG)
K. Helle (Norway)	H. Thoenen (FRG)
O. Hornykiewicz (Austria)	S. Udenfriend (USA)
L. Iversen (UK)	N. Weiner (USA)
S. Iversen (UK)	D. de Wied (The Netherlands)
G. Jaim-Etcheverry (Argentina)	R. Wurtman (USA)

International Finance Committee

E. Usdin (chairman) (USA)	S. Langer (France)
J. Engel (Sweden)	M. Rand (Australia)
J. Glowinski (France)	M. Sandler (U.K.)
G. Jaim-Etcheverry (Argentina)	S. Snyder (USA)
J. Jonason (Sweden)	R. Wurtman (USA)

Scientific Program Committee

A. Dahlström (chairman)
O. Almgren
J. Engel
J. Jonason
S.O. Ögren

Consultants

N.-E. Andén	L. Lundholm
E. Änggård	L. Olson
M. Åsberg	L. Orelund
A. Björklund	C. Owman
B. Folkow	B.-E. Roos
B. Fredholm	S. Rosell
K. Fuxe	G. Sedvall
C.-G. Gottfries	Å. Seiger
L.-M. Gunne	F. Sjöqvist
P. Hjerdal	U. Stenevi
T. Hökfelt	L. Stjärne
G. Jonsson	U. Ungerstedt
H. Lagercrantz	

Local Organizing Committee

J. Jonason (chairman)
A. Dahlström
J. Engel
T. Eriksson
M. Henning
T. Magnusson

ACKNOWLEDGMENTS

For generous support the 5 CA Symposium is obliged to:

Activational System, Pittsburgh, PA, USA
Astra Läkemedel AB, Södertälje, Sweden
Beecham Products, Betchworth, Surrey, UK
Boehringer Ingelheim AB, Skärholmen, Sweden
Boots Company Ltd., Nottingham, UK
Brocades (GB) Ltd., Weybridge, Surrey, UK
Burroughs Wellcome Co., Research Triangle Park, NC, USA
Ciba-Geigy AG, Basel, Switzerland
Ciba-Geigy Läkemedel AB, V. Frölunda, Sweden
Ciba-Geigy Corp., Summit, NJ, USA
Essex Läkemedel AB, Stockholm, Sweden
Ferring AB, Malmö, Sweden
Ferrosan AB, Malmö, Sweden
Fidia Research Laboratories, Abano Terme, Italy
Glaxo Laboratories Ltd., Ware, Herts., UK
Hoechst (UK) Ltd., Hounslow, Middlesex, UK
Hoffman La Roche Inc., Nutley, NJ, USA
Hässle AB, Mölndal, Sweden